These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 29924507)

  • 1. Relapse After Antipsychotic Discontinuation in Schizophrenia as a Withdrawal Phenomenon vs Illness Recurrence: A Post Hoc Analysis of a Randomized Placebo-Controlled Study.
    Emsley R; Nuamah I; Gopal S; Hough D; Fleischhacker WW
    J Clin Psychiatry; 2018 Jun; 79(4):. PubMed ID: 29924507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does Half-Life Matter After Antipsychotic Discontinuation? A Relapse Comparison in Schizophrenia With 3 Different Formulations of Paliperidone.
    Weiden PJ; Kim E; Bermak J; Turkoz I; Gopal S; Berwaerts J
    J Clin Psychiatry; 2017 Jul; 78(7):e813-e820. PubMed ID: 28640988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study.
    Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Janik A; Schotte A; Hough D; Fleischhacker WW
    Int J Neuropsychopharmacol; 2016 Jul; 19(7):. PubMed ID: 26902950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder.
    Joshi K; Lin J; Lingohr-Smith M; Fu DJ
    J Med Econ; 2015; 18(8):629-36. PubMed ID: 25800457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.
    Berwaerts J; Liu Y; Gopal S; Nuamah I; Xu H; Savitz A; Coppola D; Schotte A; Remmerie B; Maruta N; Hough DW
    JAMA Psychiatry; 2015 Aug; 72(8):830-9. PubMed ID: 25820612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies.
    Savitz AJ; Xu H; Gopal S; Nuamah I; Mathews M; Soares B
    Braz J Psychiatry; 2019; 41(6):499-510. PubMed ID: 30994855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of paliperidone palmitate long-acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia.
    Brown B; Turkoz I; Mancevski B; Mathews M
    Early Interv Psychiatry; 2020 Aug; 14(4):428-438. PubMed ID: 31515972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefit-risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophrenia.
    Levitan B; Markowitz M; Turkoz I; Fu DJ; Gopal S; Alphs L
    Int Clin Psychopharmacol; 2016 Nov; 31(6):315-22. PubMed ID: 27434314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
    Hough D; Gopal S; Vijapurkar U; Lim P; Morozova M; Eerdekens M
    Schizophr Res; 2010 Feb; 116(2-3):107-17. PubMed ID: 19959339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paliperidone palmitate once-every-3-months in adults with early illness schizophrenia.
    Bell Lynum KS; Turkoz I; Kim E
    Early Interv Psychiatry; 2019 Jun; 13(3):667-672. PubMed ID: 29968279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discontinuation and relapse with paliperidone palmitate three-monthly for maintenance of schizophrenia: Two year follow-up of use in clinical practice.
    Wallman P; Clark I; Taylor D
    J Psychopharmacol; 2021 Sep; 35(9):1091-1098. PubMed ID: 33908302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Potentially Prolactin-Related Adverse Events and Sexual Maturation in Adolescents with Schizophrenia Treated with Paliperidone Extended-Release (ER) for 2 Years: A Post Hoc Analysis of an Open-Label Multicenter Study.
    Gopal S; Lane R; Nuamah I; Copenhaver M; Singh J; Hough D; Bach M; Savitz A
    CNS Drugs; 2017 Sep; 31(9):797-808. PubMed ID: 28660406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder.
    Fu DJ; Turkoz I; Simonson RB; Walling DP; Schooler NR; Lindenmayer JP; Canuso CM; Alphs L
    J Clin Psychiatry; 2015 Mar; 76(3):253-62. PubMed ID: 25562685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study.
    Mayoral-van Son J; de la Foz VO; Martinez-Garcia O; Moreno T; Parrilla-Escobar M; Valdizan EM; Crespo-Facorro B
    J Clin Psychiatry; 2016 Apr; 77(4):492-500. PubMed ID: 26759992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world data on paliperidone palmitate for the treatment of schizophrenia and other psychotic disorders: a systematic review of randomized and nonrandomized studies.
    Emsley R; Parellada E; Bioque M; Herrera B; Hernando T; García-Dorado M
    Int Clin Psychopharmacol; 2018 Jan; 33(1):15-33. PubMed ID: 28817397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia.
    Schreiner A; Aadamsoo K; Altamura AC; Franco M; Gorwood P; Neznanov NG; Schronen J; Ucok A; Zink M; Janik A; Cherubin P; Lahaye M; Hargarter L
    Schizophr Res; 2015 Dec; 169(1-3):393-399. PubMed ID: 26431793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting psychotic relapse following randomised discontinuation of paliperidone in individuals with schizophrenia or schizoaffective disorder: an individual participant data analysis.
    Brandt L; Ritter K; Schneider-Thoma J; Siafis S; Montag C; Ayrilmaz H; Bermpohl F; Hasan A; Heinz A; Leucht S; Gutwinski S; Stuke H
    Lancet Psychiatry; 2023 Mar; 10(3):184-196. PubMed ID: 36804071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
    Schreiner A; Caspi A; Bergmans P; Cherubin P; Keim S; Lara E; Pinchuk I; Schuepbach D; Suleman S; Hargarter L
    Psychopharmacology (Berl); 2017 Jan; 234(1):3-13. PubMed ID: 27815602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia.
    El Khoury AC; Pilon D; Morrison L; Shak N; Vermette-Laforme M; Amos TB; Kim E; Lefebvre P
    Curr Med Res Opin; 2019 Mar; 35(3):395-405. PubMed ID: 30526125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment effect with paliperidone palmitate compared with oral antipsychotics in patients with recent-onset versus more chronic schizophrenia and a history of criminal justice system involvement.
    Alphs L; Bossie C; Mao L; Lee E; Starr HL
    Early Interv Psychiatry; 2018 Feb; 12(1):55-65. PubMed ID: 26403322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.